During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Growing from a small community led initiative to a major fundraiser, the The Walk of Champions began with a modest $12,000 ...

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

Co-owner of Burlington’s Finnigan’s Pub for more than 32 years was known for his work ethic, great attitude and remarkable ...

Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19 ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), ...

Investment analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX – Get Free Report) in a research note issued on Saturday. The brokerage set a “hold” rating on the biotechnology ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

“I was dumbfounded,” said Clive Webb, a cancer patient at Juravinski Hospital who also co-leads Hamilton support group ...